Holen Sie sich die Stockscreener-App
38.86
5.54%
-2.28
Schlusskurs vom Vortag:
$41.14
Offen:
$41.14
24-Stunden-Volumen:
2.16M
Relative Volume:
0.91
Marktkapitalisierung:
$4.51B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-472.34M
KGV:
-9.3731
EPS:
-4.1459
Netto-Cashflow:
$-340.33M
1W Leistung:
+3.79%
1M Leistung:
+40.04%
6M Leistung:
+21.48%
1J Leistung:
+24.19%
1-Tages-Spanne:
$38.18
$41.14
1-Wochen-Bereich:
$37.10
$42.79
52-Wochen-Spanne:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Firmenname
Viking Therapeutics Inc
Sektor
Branche
Telefon
858-704-4660
Adresse
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
38.86 | 4.51B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Goldman | Neutral |
| 2025-02-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-07 | Eingeleitet | Citigroup | Neutral |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-22 | Eingeleitet | B. Riley Securities | Buy |
| 2024-11-04 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-11 | Eingeleitet | JP Morgan | Overweight |
| 2024-06-27 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-07 | Eingeleitet | Jefferies | Buy |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2023-05-31 | Fortgesetzt | ROTH MKM | Buy |
| 2023-03-28 | Bestätigt | Maxim Group | Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2021-07-29 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-05-01 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-25 | Eingeleitet | Stifel | Buy |
| 2019-03-29 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Bestätigt | Maxim Group | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-11-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-18 | Bestätigt | Maxim Group | Buy |
| 2018-09-18 | Bestätigt | Raymond James | Outperform |
| 2018-07-20 | Eingeleitet | SunTrust | Buy |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-01 | Bestätigt | Laidlaw | Buy |
| 2018-05-31 | Bestätigt | Maxim Group | Buy |
| 2018-03-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | Maxim Group | Buy |
| 2017-11-21 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Viking Therapeutics Inc Aktie (VKTX) Neueste Nachrichten
Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market - Kavout | AI
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics, Inc. (VKTX) stock falls amid market uptick: What investors need to know - MSN
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy? - Sahm
(VKTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Here’s How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 10 Years - Benzinga
Viking Therapeutics: Still Cheap, But Watch Double Top (NASDAQ:VKTX) - Seeking Alpha
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
Is Viking Therapeutics Stock Going to $100? - AOL.com
Here's Why Viking Therapeutics Stock Surged Higher in June - AOL.com
Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength - FXEmpire
Is This Biotech Stock a Buy After Its Massive Rally? - The Motley Fool
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? - AOL.com
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation? - Yahoo Finance
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? - AOL.com
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today - Yahoo Finance
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - AOL.com
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
Is It Too Late to Buy Eli Lilly? - The Motley Fool
LLY Hits Another Record High: Is the Stock Too Expensive to Buy Now? - TradingView
Viking Therapeutics (VKTX) Stock Looks Stretched After a 6x Five Year Run - Yahoo Finance
Viking Therapeutics (VKTX) Stock Looks Pricey After New Obesity Trial Launch - simplywall.st
Piper Sandler Sticks to Its Buy Rating for Viking Therapeutics (VKTX) - The Globe and Mail
Viking Therapeutics, Inc. (VKTX) Stock Price Quote Today & Current Price Chart - Capital.com
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Viking Therapeutics (VKTX) Could Be 120% Undervalued On Obesity Pipeline Progress - Yahoo Finance
Viking Therapeutics (VKTX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Why Viking Therapeutics (VKTX) Is Up 8.0% After Advancing New Obesity Drug VK3019 Into Phase 1 – And What's Next - Yahoo Finance
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal? - Yahoo Finance
Viking Therapeutics Gains as Obesity Pipeline Momentum Builds - Quiver Quantitative
Viking Therapeutics (VKTX) Q2 2024 earnings summary - Quartr
Viking Therapeutics (VKTX) Proxy filing Summary - Quartr
Viking Therapeutics (VKTX) Corporate presentation Summary - Quartr
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer - AOL.com
CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026? - The Motley Fool
Piper Sandler reiterates Overweight on Viking Therapeutic stock By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Overweight on Viking Therapeutic stock - Investing.com
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Piper Sandler Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $71 - Moomoo
Viking Therapeutics (VKTX) Starts VK3019 Trial As Obesity Pipeline Narrative Meets Valuation - simplywall.st
Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030 - foreignpolicyjournal.com
OABI,VKTX Revenue Breakdown - Finviz
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? - Yahoo Finance
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Quick ratio of Viking Therapeutics, Inc. – XETR:1VT - TradingView
Viking Therapeutics' Prospects in the Weight Loss Drug Market - Intellectia AI
Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):